Abstract
Precis: UFT 300 mg/m2/day and leucovorin 90 mg/day could be administered safely to patients with advanced biliary cancer with good performance status; however, this combination and schedule of 28-day administration has no activity in this disease.
Purpose: To determine the activity and evaluate the toxicity of uracil and tegafur in a 4:1 molar concentration ratio (UFT; Bristol-Myers Squibb, Wallingford, CT) plus oral calcium leucovorin in the treatment of patients with advanced biliary (gallbladder and bile duct) carcinoma.
Patients and methods: Thirteen patients with advanced measurable biliary carcinoma were enrolled onto the trial. All patients had a Karnofsky performance status ≥ 60%, platelet count ≥ 75,000/μL, total bilirubin ≤ 2.0× institutional upper limit of normal but otherwise normal liver and kidney function profile and bidimensionally measurable disease by CT scan or ultrasound examination. None of these patients previously received cytotoxic chemotherapy or radiation therapy for advanced disease. Patients received 300 mg/m2/d UFT plus 90 mg/d leucovorin administered orally in divided daily doses every 8 hours for 28 days repeated every 35 days. Objective tumor response, the primary endpoint of this trial, was evaluated after two courses of therapy. Other endpoints included toxicity, time to progression, and overall survival.
Results: All patients were evaluable for response and toxicity. No complete or partial responses were observed in this trial. Four patients had stable disease lasting 17, 30, 33, and 35 weeks, respectively. The median (range) time to progression and survival were 9 (1–35) and 28 (1–61) weeks, respectively. Treatment-related toxicity was mild with severe (grade 3 or 4) diarrhea seen in 2 (15%). Grade 3–4 hyperbilirubinemia (31%) and nausea/vomiting (31%) were observed and likely related to the underlying disease. Grade 1 and 2 toxic effects included mainly anorexia and fatigue.
Conclusion: UFT 300 mg/m2/d plus oral leucovorin 90 mg/d administered for 28 days repeated every 35 days is ineffective in the treatment of advanced biliary carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Haskell CM: Cancer of the liver. In: Haskell CM (ed), Cancer Treatment. Philadelphia: WB Saunders, 1980, pp 319–357
Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54: 965, 1984
Maehara Y, Kakeji Y, Ohno S et al.: Scientific basis for the combination of tegafur with uracil. Oncol 11(9) (Suppl 10): 14–16, 1997
Pazdur R: Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncol 11(9) (Suppl 10): 35–38, 1997
Taguchi T, Nakano H, Jikuya H et al.: Effect of uracil on the antitumor activity of florafur. Jpn J Cancer Chemother 5: 1161–1165, 1978
Taguchi T, Furue H, Koyanna Y et al.: Phase I study of UFT. Jpn J Cancer Chemother 7: 966–972, 1980
Nakajima O, Ihara K, Isoda T et al.: Phase I and II studies on mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil. Jpn J Cancer Chemother 7: 1558–1568, 1980
Taguchi T: Experience with UFT in Japan. Oncol 11(9) (Suppl 10): 30–35, 1997
Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333–338, 1988
Mani S: An ongoing phase II study of UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas. Oncol 11(9) (Suppl 10): 124–128, 1997
Ajani JA, Welch SR, Raber MN et al.: Comprehensive criteria for survival and therapy-induced toxicity. Cancer Invest 8: 141–153, 1990
Pazdur R, Lassere Y, Rhodes V et al.: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296–2300, 1994
Sakata Y, Munakata A, Baba T et al.: Controlled study of MQF-OK therapy with FT and with UFT on various advanced gastrointestinal cancers. Hirosaki cooperative study group of cancer chemotherapy. Gan To Kagaku Ryoho 15: 205–271, 1988
Koda K, Nakazawa O, Morita K et al.: Combination chemotherapy of UFT and adriamycin and cisplatin for advanced gastrointestinal cancer. Gan To Kagaku Ryoho 17: 1893–1900, 1990
Koda K, Kure T, Terada S et al.: Combination chemotherapy of UFT with adriamycin in advanced gastrointestinal cancer. Gan No Rinsho 33: 1329–1335, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mani, S., Sciortino, D., Samuels, B. et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 17, 97–101 (1999). https://doi.org/10.1023/A:1006268018519
Issue Date:
DOI: https://doi.org/10.1023/A:1006268018519